Riello Investimenti SGR, through its Linfa fund, has invested in Exolab Italia to enhance its production capabilities and establish it as a global leader in plant-based exosome ingredients.

Target Company Overview

Exolab Italia, headquartered in Milan, is a leading market player in the innovation of natural functional assets. The company specializes in the production of plant-based exosome ingredients, which are increasingly in demand in various sectors including cosmetics, pharmaceuticals, and food industries. With a strong focus on research and development, Exolab has positioned itself at the forefront of technological advancements, making significant strides in enhancing the efficacy and sustainability of its products.

This investment by Riello Investimenti SGR is a strategic move to enhance Exolab’s production capabilities and market reach. Exolab’s commitment to innovation and quality ensures that the company remains competitive in an evolving market landscape, where natural ingredients are becoming paramount.

Industry Overview in Italy

The Italian market for natural ingredients is witnessing remarkable growth, driven by increasing consumer demand for sustainable and organic products. The cosmetics and personal care sector, in particular, is shifting towards natural formulations,